title: Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.
abstract: Peer-reviewed data pertaining to anti-thrombotic and interventional therapy for transient ischaemic attack (TIA) or ischaemic stroke patients with non-valvular atrial fibrillation, atrial flutter, interatrial septal abnormalities, or left ventricular thrombus were reviewed. Long-term oral anticoagulant therapy with warfarin is the treatment of choice for secondary stroke prevention following TIA or minor ischaemic stroke in association with persistent or paroxysmal non-valvular atrial fibrillation or atrial flutter. If warfarin is contraindicated, long-term aspirin is a safe, but much less effective alternative treatment option in this subgroup of patients with cerebrovascular disease. Management of young patients with TIA or stroke in association with an interatrial septal defect is controversial. Various treatment options are outlined, but readers are encouraged to include these patients in one of the ongoing randomised clinical trials in this area. It is reasonable to consider empirical anticoagulation in patients with TIA or ischaemic stroke in association with left ventricular thrombus formation following myocardial infarction or in association with idiopathic dilated cardiomyopathy. If warfarin is prescribed, one should aim for a target international normalised ratio of 2.5 (range 2-3) to achieve the best balance between adequate secondary prevention of cardioembolic events and the risk of major haemorrhagic complications.
authors.affiliation: Department of Neurology, The Adelaide and Meath Hospital Tallaght, Trinity College Dublin, Dublin 24, Republic of Ireland. dominick.mccabe@amnch.ie
authors.forename: D J H
authors.initials: DJ
authors.lastname: McCabe
authors.forename: R D
authors.initials: RD
authors.lastname: Rakhit
mesh_terms: D000367:Age Factors; D000925:Anticoagulants / Q000627:therapeutic use*; D020517:Atrial Appendage / Q000601:surgery; D001281:Atrial Fibrillation / Q000150:complications; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006331:Heart Diseases / Q000150:complications; D006344:Heart Septal Defects, Atrial / Q000150:complications; D006801:Humans; D020766:Intracranial Embolism / Q000150:complications / Q000209:etiology; D002546:Ischemic Attack, Transient / Q000188:drug therapy* / Q000209:etiology; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology; D013927:Thrombosis / Q000150:complications
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents